Skip to main content

Cost-effectiveness and net benefit of enhanced treatment of depression for older adults with diabetes and depression.

Publication ,  Journal Article
Katon, W; Unützer, J; Fan, M-Y; Williams, JW; Schoenbaum, M; Lin, EHB; Hunkeler, EM
Published in: Diabetes Care
February 2006

OBJECTIVE: To determine the incremental cost-effectiveness and net benefit of a depression collaborative care program compared with usual care for patients with diabetes and depression. RESEARCH DESIGN AND METHODS: This article describes a preplanned subgroup analysis of patients with diabetes from the Improving Mood-Promoting Access to Collaborative (IMPACT) randomized controlled trial. The setting for the study included 18 primary care clinics from eight health care organizations in five states. A total of 418 of 1,801 patients randomized to the IMPACT intervention (n = 204) versus usual care (n = 214) had coexisting diabetes. A depression care manager offered education, behavioral activation, and a choice of problem-solving treatment or support of antidepressant management by the primary care physician. The main outcomes were incremental cost-effectiveness and net benefit of the program compared with usual care. RESULTS: Relative to usual care, intervention patients experienced 115 (95% CI 72-159) more depression-free days over 24 months. Total outpatient costs were 25 dollars (95% CI -1,638 to 1,689) higher during this same period. The incremental cost per depression-free day was 25 cents (-14 dollars to 15 dollars) and the incremental cost per quality-adjusted life year ranged from 198 dollars (144-316) to 397 dollars (287-641). An incremental net benefit of 1,129 dollars (692-1,572) was found. CONCLUSIONS: The IMPACT intervention is a high-value investment for older adults with diabetes; it is associated with high clinical benefits at no greater cost than usual care.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Diabetes Care

DOI

ISSN

0149-5992

Publication Date

February 2006

Volume

29

Issue

2

Start / End Page

265 / 270

Location

United States

Related Subject Headings

  • Quality-Adjusted Life Years
  • Outcome Assessment, Health Care
  • Male
  • Humans
  • Health Care Costs
  • Female
  • Endocrinology & Metabolism
  • Diabetes Mellitus, Type 2
  • Depressive Disorder
  • Cost-Benefit Analysis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Katon, W., Unützer, J., Fan, M.-Y., Williams, J. W., Schoenbaum, M., Lin, E. H. B., & Hunkeler, E. M. (2006). Cost-effectiveness and net benefit of enhanced treatment of depression for older adults with diabetes and depression. Diabetes Care, 29(2), 265–270. https://doi.org/10.2337/diacare.29.02.06.dc05-1572
Katon, Wayne, Jürgen Unützer, Ming-Yu Fan, John W. Williams, Michael Schoenbaum, Elizabeth H. B. Lin, and Enid M. Hunkeler. “Cost-effectiveness and net benefit of enhanced treatment of depression for older adults with diabetes and depression.Diabetes Care 29, no. 2 (February 2006): 265–70. https://doi.org/10.2337/diacare.29.02.06.dc05-1572.
Katon W, Unützer J, Fan M-Y, Williams JW, Schoenbaum M, Lin EHB, et al. Cost-effectiveness and net benefit of enhanced treatment of depression for older adults with diabetes and depression. Diabetes Care. 2006 Feb;29(2):265–70.
Katon, Wayne, et al. “Cost-effectiveness and net benefit of enhanced treatment of depression for older adults with diabetes and depression.Diabetes Care, vol. 29, no. 2, Feb. 2006, pp. 265–70. Pubmed, doi:10.2337/diacare.29.02.06.dc05-1572.
Katon W, Unützer J, Fan M-Y, Williams JW, Schoenbaum M, Lin EHB, Hunkeler EM. Cost-effectiveness and net benefit of enhanced treatment of depression for older adults with diabetes and depression. Diabetes Care. 2006 Feb;29(2):265–270.

Published In

Diabetes Care

DOI

ISSN

0149-5992

Publication Date

February 2006

Volume

29

Issue

2

Start / End Page

265 / 270

Location

United States

Related Subject Headings

  • Quality-Adjusted Life Years
  • Outcome Assessment, Health Care
  • Male
  • Humans
  • Health Care Costs
  • Female
  • Endocrinology & Metabolism
  • Diabetes Mellitus, Type 2
  • Depressive Disorder
  • Cost-Benefit Analysis